

10/12/2005 10777252.trn

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,  
STN AnaVist, now available  
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America  
NEWS 5 AUG 30 CA/CAPLUS - Increased access to 19th century research documents  
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions  
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY  
NEWS 8 OCT 03 MATHDI removed from STN  
NEWS 9 OCT 04 CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added  
to core patent offices  
NEWS 10 OCT 06 STN AnaVist workshops to be held in North America

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

```
FILE 'HOME' ENTERED AT 09:32:24 ON 12 OCT 2005

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n) :
Switching to the Registry File...
Some commands only work in certain files.  For
```

10/12/2005 10777252.trn

command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:32:35 ON 12 OCT 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 OCT 2005 HIGHEST RN 865062-68-6  
DICTIONARY FILE UPDATES: 11 OCT 2005 HIGHEST RN 865062-68-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.


\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\10777252.str



chain nodes :

14 16

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13

chain bonds :

5-16 12-14

ring bonds :

1-2 1-6 2-3 3-4 4-7 5-6 5-9 6-7 7-10 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

5-6 5-9 5-16 12-14

exact bonds :

7-10 8-9 8-13 9-10 10-11 11-12 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-7 6-7

isolated ring systems :

containing 1 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=&gt; d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 09:32:48 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 63 TO ITERATE

100.0% PROCESSED 63 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 784 TO 1736  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 sss full  
FULL SEARCH INITIATED 09:32:54 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1092 TO ITERATE

100.0% PROCESSED 1092 ITERATIONS  
SEARCH TIME: 00.00.01

L3 2 SEA SSS FUL L1

=> FIL HCAPLUS  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
161.33 161.54

FILE 'HCAPLUS' ENTERED AT 09:33:01 ON 12 OCT 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

2 ANSWERS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Oct 2005 VOL 143 ISS 16  
FILE LAST UPDATED: 11 Oct 2005 (20051011/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.



=> s 13  
L4 1 L3

=> d 14 ibib abs hitstr tot

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2003:300887 HCAPLUS  
DOCUMENT NUMBER: 138:321126  
TITLE: Preparation of arylsulphonyl-substituted tetrahydro-  
and hexahydrocarbazolamines as 5-HT6 receptor ligands  
INVENTOR(S): Fu, Jian-Min  
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
SOURCE: PCT Int. Appl., 66 pp.  
CODEN: PIIXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003030901	A1	20030417	WO 2002-US32353	20021008
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2461369	AA	20030417	CA 2002-2461369	20021008
US 2003100596	A1	20030529	US 2002-268627	20021008
US 6727274	B2	20040427		
EP-1434578	A1	20040707	EP 2002-776201	20021008
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013208	A	20040831	BR 2002-13208	20021008
JP 2005508349	T2	20050331	JP 2003-533933	20021008
US 2004162332	A1	20040819	US 2004-777252	20040212
PRIORITY APPLN. INFO.:				
		US 2001-327875P	P	20011009
		US 2001-327876P	P	20011009
		US 2002-268627	A3	20021008
		WO 2002-US32353	W	20021008

OTHER SOURCE(S) : MARPAT 138:321126  
GI



AB The invention provides arylsulfonyl-substituted tetrahydro- and hexahydrocarbazoles (shown as I; variables defined below; e.g. 6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine hydrochloride (base shown as II)) for use in treating conditions in which 5-HT<sub>6</sub> receptors are involved such as in anxiety, depression, schizophrenia, Alzheimer's disease, stress-related disease, panic, a phobia, obsessive compulsive disorder, obesity, post-traumatic stress syndrome, epilepsy, and other CNS disorders. Binding consts. (Ki) for the examples to 5-HT<sub>6</sub> receptors are apprx. 2.9-58 nM. The 3R isomers of the tetrahydrocarbazoles exhibit higher selectivity towards the 5-HT<sub>6</sub> serotonin receptor relative to the 3S isomer. Isotopically labeled I are claimed to be useful for performing positron emission tomog. Although the methods of preparation are not claimed, 5 example prepns. of I and intermediates are included. For I: the bond labeled [b] is a single or double bond; each X, Y, and Z = H, -OH, -O-alkyl, and -O-substituted alkyl; R1 = H, (un)substituted alkyl, (un)substituted cycloalkyl, and aryl; R2 = H, (un)substituted alkyl, (un)substituted cycloalkyl, and aryl; R3 = H, (un)substituted alkyl, (un)substituted cycloalkyl, and -A-E-R8; A = (un)substituted alkyl. E = -N(R10)C(O)-, -C(O)N(R10)-, -N(R10)C(S)-, -C(S)N(R10)-, -S(O)N(R10)-, -N(R10)S(O)-, -S(O)2N(R10)-, and -N(R10)S(O)2-. Each R4, R5, R6, and R7 = H, halogen, aryl, -CN, -NO<sub>2</sub>, (un)substituted alkyl, (un)substituted cycloalkyl, -OR<sub>9</sub>, -NH<sub>2</sub>, -C(O)NH<sub>2</sub>, -C(S)NH<sub>2</sub>, and -S(O)naryl, provided that one of R4, R5, R6, and R7 is -S(O)naryl, and that at least one of R4, R5, R6, and R7 is H; n = 0-2. Each R8, R9, and R10 = H, (un)substituted alkyl, (un)substituted cycloalkyl, and aryl; each R11 = H, (un)substituted alkyl, (un)substituted cycloalkyl, heterocycloalkyl, Ph, naphthyl, and heteroarom., provided that any of the alkyl, cycloalkyl, Ph, naphthyl, or heteroarom. is optionally substituted with up to 3 substituents = halogen, alkyl, -CF<sub>3</sub>, -OR<sub>12</sub>, -SR<sub>12</sub>, -CN, -NO<sub>2</sub>, -N<sub>3</sub>, -N(R<sub>12</sub>)<sub>2</sub>, -C(O)N(R<sub>12</sub>)<sub>2</sub>, and -C(S)N(R<sub>12</sub>)<sub>2</sub>; each R<sub>12</sub> = H, alkyl, and cycloalkyl, provided that any of the alkyl or cycloalkyl is optionally substituted with up to 2 substituents = halogen, -CF<sub>3</sub>, -NO<sub>2</sub>, -NH<sub>2</sub>, -N<sub>3</sub>, -CN, -OH, -O-lower alkyl, and -O-lower substituted alkyl.

IT 512204-84-1P, (3R)-9-Methyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-


hexahydro-1H-carbazol-3-amine **512204-88-5P**, (3S)-9-Methyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine  
 RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(candidate drug and positron-emission tomog. uses; preparation of arylsulfonyl-substituted tetrahydro- and hexahydrocarbazolamines as 5-HT<sub>6</sub> receptor ligands)

RN 512204-84-1 HCAPLUS

CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-9-methyl-6-(phenylsulfonyl)-, (3R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 512204-88-5 HCAPLUS

CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-9-methyl-6-(phenylsulfonyl)-, (3S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

FULL ESTIMATED COST

TOTAL  
SESSION

7.39 168.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE  
ENTRY

CA SUBSCRIBER PRICE

TOTAL  
SESSION

-0.73 -0.73

FILE 'REGISTRY' ENTERED AT 09:33:48 ON 12 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 OCT 2005 HIGHEST RN 865062-68-6  
DICTIONARY FILE UPDATES: 11 OCT 2005 HIGHEST RN 865062-68-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> FIL STNGUIDE	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	0.43	169.36
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-0.73

FILE 'STNGUIDE' ENTERED AT 09:34:23 ON 12 OCT 2005  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Oct 7, 2005 (20051007/UP).

=> FIL REGISTRY	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	0.06	169.42
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-0.73

10/12/2005 10777252.trn

FILE 'REGISTRY' ENTERED AT 09:34:34 ON 12 OCT 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 OCT 2005 HIGHEST RN 865062-68-6  
DICTIONARY FILE UPDATES: 11 OCT 2005 HIGHEST RN 865062-68-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.


\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\10777252a.str



chain nodes :  
14  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 13  
chain bonds :  
12-14  
ring bonds :  
1-2 1-6 2-3 3-4 4-7 5-6 5-9 6-7 7-10 8-9 8-13 9-10 10-11 11-12 12-13  
exact/norm bonds :  
5-6 5-9 12-14

10/12/2005 10777252.trn

exact bonds :

7-10 8-9 8-13 9-10 10-11 11-12 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-7 6-7

isolated ring systems :

containing 1 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:CLASS

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 15

SAMPLE SEARCH INITIATED 09:34:51 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 63 TO ITERATE

100.0% PROCESSED 63 ITERATIONS  
SEARCH TIME: 00.00.01

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 784 TO 1736  
PROJECTED ANSWERS: 2 TO 124

L6 2 SEA SSS SAM L5

=> s 15 sss full

FULL SEARCH INITIATED 09:34:58 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1092 TO ITERATE

100.0% PROCESSED 1092 ITERATIONS  
SEARCH TIME: 00.00.01



9 ANSWERS

L7 9 SEA SSS FUL L5

=>

10/12/2005 10777252.trn

Uploading C:\Program Files\Stnexp\Queries\10777252b.str



chain nodes :

15

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13

chain bonds :

12-15

ring bonds :

1-2 1-6 2-3 3-4 4-7 5-6 5-9 6-7 7-10 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

5-6 5-9 12-15

exact bonds :

7-10 8-9 8-13 9-10 10-11 11-12 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-7 6-7

isolated ring systems :

containing 1 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 15:CLASS

L8 STRUCTURE UPLOADED

=> d 18

L8 HAS NO ANSWERS

L8 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 18

SAMPLE SEARCH INITIATED 09:36:06 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 63 TO ITERATE

10/12/2005 10777252.trn

100.0% PROCESSED 63 ITERATIONS  
SEARCH TIME: 00.00.01

4 ANSWERS

FULL FILE PROJECTIONS:	ONLINE	**COMPLETE**
	BATCH	**COMPLETE**
PROJECTED ITERATIONS:	784 TO	1736
PROJECTED ANSWERS:	4 TO	200

L9 4 SEA SSS SAM L8

=> s 18 sss full  
FULL SEARCH INITIATED 09:36:13 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1092 TO ITERATE

100.0% PROCESSED 1092 ITERATIONS  
SEARCH TIME: 00:00:01

49 ANSWERS

L10 49 SEA SSS EUL 1.8

=> d his

(FILE 'HOME' ENTERED AT 09:32:24 ON 12 OCT 2005)

FILE 'REGISTRY' ENTERED AT 09:32:35 ON 12 OCT 2005

L1 STRUCTURE uploaded  
L2 0 S L1  
L3 2 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 09:33:01 ON 12 OCT 2005

L4 1 S L3

FILE 'REGISTRY' ENTERED AT 09:33:48 ON 12 OCT 2005

FILE 'STNGUIDE' ENTERED AT 09:34:23 ON 12 OCT 2005

FILE 'REGISTRY' ENTERED AT 09:34:34 ON 12 OCT 2005

L6 2 S L5  
L7 9 S L5 SSS FULL  
L8 STRUCTURE uploaded  
L9 4 S L8  
L10 49 S L8 SSS FULL

=> FIL HCAPLUS  
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
323.09	492.51

**DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)**

SINCE FILE ENTRY	TOTAL SESSION
0.00	0.73

FILE 'HCAPLUS' ENTERED AT 09:36:33 ON 12 OCT 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the original author(s).

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Oct 2005 VOL 143 ISS 16  
FILE LAST UPDATED: 11 Oct 2005 (20051011/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.



=> s 17  
L11            2 L7  
=> s 110  
L12            9 L10  
=> d 111 ibib abs hitstr tot

L11 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2003:300887 HCAPLUS  
DOCUMENT NUMBER: 138:321126  
TITLE: Preparation of arylsulphonyl-substituted tetrahydro-  
and hexahydrocarbazolamines as 5-HT6 receptor ligands  
INVENTOR(S): Fu, Jian-Min  
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
SOURCE: PCT Int. Appl., 66 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003030901	A1	20030417	WO 2002-US32353	20021008
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2461369	AA	20030417	CA 2002-2461369	20021008
US 2003100596	A1	20030529	US 2002-268627	20021008
US 6727274	B2	20040427		
EP 1434578	A1	20040707	EP 2002-776201	20021008
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013208	A	20040831	BR 2002-13208	20021008

JP 2005508349	T2	20050331	JP 2003-533933	20021008
US 2004162332	A1	20040819	US 2004-777252	20040212
PRIORITY APPLN. INFO.:			US 2001-327875P	P 20011009
			US 2001-327876P	P 20011009
			US 2002-268627	A3 20021008
			WO 2002-US32353	W 20021008

OTHER SOURCE(S) : MARPAT 138:321126  
GI



AB The invention provides arylsulfonyl-substituted tetrahydro- and hexahydrocarbazoles (shown as I; variables defined below; e.g. 6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine hydrochloride (base shown as II)) for use in treating conditions in which 5-HT<sub>6</sub> receptors are involved such as in anxiety, depression, schizophrenia, Alzheimer's disease, stress-related disease, panic, a phobia, obsessive compulsive disorder, obesity, post-traumatic stress syndrome, epilepsy, and other CNS disorders. Binding consts. (Ki) for the examples to 5-HT<sub>6</sub> receptors are .apprx.2.9-58 nM. The 3R isomers of the tetrahydrocarbazoles exhibit higher selectivity towards the 5-HT<sub>6</sub> serotonin receptor relative to the 3S isomer. Isotopically labeled I are claimed to be useful for performing positron emission tomog. Although the methods of preparation are not claimed, 5 example prepn. of I and intermediates are included. For I: the bond labeled [b] is a single or double bond; each X, Y, and Z = H, -OH, -O-alkyl, and -O-substituted alkyl; R1 = H, (un)substituted alkyl, (un)substituted cycloalkyl, and aryl; R2 = H, (un)substituted alkyl, (un)substituted cycloalkyl, and aryl; R3 = H, (un)substituted alkyl, (un)substituted cycloalkyl, and -A-E-R8; A = (un)substituted alkyl. E = -N(R10)C(O)-, -C(O)N(R10)-, -N(R10)C(S)-, -C(S)N(R10)-, -S(O)N(R10)-, -N(R10)S(O)-, -S(O)2N(R10)-, and -N(R10)S(O)2-. Each R4, R5, R6, and R7 = H, halogen, aryl, -CN, -NO<sub>2</sub>, (un)substituted alkyl, (un)substituted cycloalkyl, -OR9, -NH<sub>2</sub>, -C(O)NH<sub>2</sub>, -C(S)NH<sub>2</sub>, and -S(O)naryl, provided that one of R4, R5, R6, and R7 is -S(O)naryl, and that at least one of R4, R5, R6, and R7 is H; n = 0-2. Each R8, R9, and R10 = H, (un)substituted alkyl, (un)substituted cycloalkyl, and aryl; each R11 = H, (un)substituted alkyl, (un)substituted cycloalkyl, heterocycloalkyl, Ph, naphthyl, and heteroarom., provided that any of the alkyl, cycloalkyl, Ph, naphthyl, or heteroarom. is optionally


substituted with up to 3 substituents = halogen, alkyl, -CF<sub>3</sub>, -OR<sub>12</sub>, -SR<sub>12</sub>, -CN, -NO<sub>2</sub>, -N<sub>3</sub>, -N(R<sub>12</sub>)<sub>2</sub>, -C(O)N(R<sub>12</sub>)<sub>2</sub>, and -C(S)-N(R<sub>12</sub>)<sub>2</sub>; each R<sub>12</sub> = H, alkyl, and cycloalkyl, provided that any of the alkyl or cycloalkyl is optionally substituted with up to 2 substituents = halogen, -CF<sub>3</sub>, -NO<sub>2</sub>, -NH<sub>2</sub>, -N<sub>3</sub>, -CN, -OH, -O-lower alkyl, and -O-lower substituted alkyl.

IT 512204-84-1P, (3R)-9-Methyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine 512204-88-5P, (3S)-9-Methyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine 512204-89-6P, (3R)-6-(Phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine 512204-90-9P, (3S)-6-(Phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine 512204-95-4P  
 RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (candidate drug and positron-emission tomog. uses; preparation of arylsulfonyl-substituted tetrahydro- and hexahydrocarbazolamines as 5-HT<sub>6</sub> receptor ligands)

RN 512204-84-1 HCPLUS

CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-9-methyl-6-(phenylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 512204-88-5 HCPLUS

CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-9-methyl-6-(phenylsulfonyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 512204-89-6 HCPLUS


CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-6-(phenylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 512204-90-9 HCAPLUS  
 CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-6-(phenylsulfonyl)-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512204-95-4 HCAPLUS  
 CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-6-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1981:47136 HCAPLUS  
 DOCUMENT NUMBER: 94:47136  
 TITLE: Tetrahydrocarbazoles and pharmaceutical compositions for treating heart failure in mammals  
 INVENTOR(S): Mooradian, Aram  
 PATENT ASSIGNEE(S): Sterling Drug Inc., USA  
 SOURCE: U.S., 7 pp. Cont.-in-part of U.S. Ser. No. 465,238, abandoned.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

US 4224335	A	<u>19800923</u>	US 1976-651882	19760123
US 3642816	A	19720215	US 1967-659606	19670810
US 3959309	A	19760525	US 1973-425205	19731217
PRIORITY APPLN. INFO.:			US 1967-659606	A2 19670810
			US 1969-793545	A2 19690123
			US 1971-172206	A2 19710816
			US 1973-425205	A2 19731217
			US 1974-465238	A2 19740429
			CA 1968-10686	A 19680124

GI




AB The carbazoles I (R = H, Me; R1 = NH<sub>2</sub>, EtNH, Me<sub>2</sub>N; R2 = 5-, 6-, 7-HO; R3 = H, 7-F, 7-HO) were prepared. Thus, m-PhCH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>NMeNH<sub>2</sub>.HCl was cyclized with 4-(dimethylamino)cyclohexanone to give I (R = Me, R1 = Me<sub>2</sub>N, R2 = 7-PhCH<sub>2</sub>O, R3 = H), which was debenzylated to give I (R = Me, R1 = Me<sub>2</sub>N, R2 = 7-HO, R3 = H). I underwent cardiotonic tests and were found useful for treatment of congestive heart failure in mammals.

IT **76243-18-0P 76243-21-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, for treatment of congestive heart failure)

RN 76243-18-0 HCPLUS


CN 1H-Carbazole-6,7-diol, 3-amino-2,3,4,4a,9,9a-hexahydro-, hydrochloride  
(9CI) (CA INDEX NAME)



• x. HCl

RN 76243-21-5 HCPLUS

CN 1H-Carbazol-7-ol, 3-amino-2,3,4,4a,9,9a-hexahydro-, hydrochloride (9CI)  
(CA INDEX NAME)





● x HCl

=&gt; d 112 ibib abs hitstr tot

L12 ANSWER 1 OF 9 HCPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:300887 HCPLUS  
 DOCUMENT NUMBER: 138:321126  
 TITLE: Preparation of arylsulphonyl-substituted tetrahydro-  
 and hexahydrocarbazolamines as 5-HT<sub>6</sub> receptor ligands  
 INVENTOR(S): Fu, Jian-Min  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
 SOURCE: PCT Int. Appl., 66 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003030901	A1	20030417	WO 2002-US32353	20021008
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2461369	AA	20030417	CA 2002-2461369	20021008
US 2003100596	A1	20030529	US 2002-268627	20021008
US 6727274	B2	20040427		
EP 1434578	A1	20040707	EP 2002-776201	20021008
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013208	A	20040831	BR 2002-13208	20021008
JP 2005508349	T2	20050331	JP 2003-533933	20021008
US 2004162332	A1	20040819	US 2004-777252	20040212
PRIORITY APPLN. INFO.:			US 2001-327875P	P 20011009
			US 2001-327876P	P 20011009
			US 2002-268627	A3 20021008
OTHER SOURCE(S): GI			WO 2002-US32353	W 20021008



**AB** The invention provides arylsulfonyl-substituted tetrahydro- and hexahydrocarbazoles (shown as I; variables defined below; e.g. 6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine hydrochloride (base shown as II)) for use in treating conditions in which 5-HT<sub>6</sub> receptors are involved such as in anxiety, depression, schizophrenia, Alzheimer's disease, stress-related disease, panic, a phobia, obsessive compulsive disorder, obesity, post-traumatic stress syndrome, epilepsy, and other CNS disorders. Binding consts. (Ki) for the examples to 5-HT<sub>6</sub> receptors are .apprx.2.9-58 nM. The 3R isomers of the tetrahydrocarbazoles exhibit higher selectivity towards the 5-HT<sub>6</sub> serotonin receptor relative to the 3S isomer. Isotopically labeled I are claimed to be useful for performing positron emission tomog. Although the methods of preparation are not claimed, 5 example prepns. of I and intermediates are included. For I: the bond labeled [b] is a single or double bond; each X, Y, and Z = H, -OH, -O-alkyl, and -O-substituted alkyl; R1 = H, (un)substituted alkyl, (un)substituted cycloalkyl, and aryl; R2 = H, (un)substituted alkyl, (un)substituted cycloalkyl, and aryl; R3 = H, (un)substituted alkyl, (un)substituted cycloalkyl, and -A-E-R8; A = (un)substituted alkyl. E = -N(R10)C(O)-, -C(O)N(R10)-, -N(R10)C(S)-, -C(S)N(R10)-, -S(O)N(R10)-, -N(R10)S(O)-, -S(O)2N(R10)-, and -N(R10)S(O)2-. Each R4, R5, R6, and R7 = H, halogen, aryl, -CN, -NO<sub>2</sub>, (un)substituted alkyl, (un)substituted cycloalkyl, -OR<sub>9</sub>, -NH<sub>2</sub>, -C(O)NH<sub>2</sub>, -C(S)NH<sub>2</sub>, and -S(O)naryl, provided that one of R4, R5, R6, and R7 is -S(O)naryl, and that at least one of R4, R5, R6, and R7 is H; n = 0-2. Each R8, R9, and R10 = H, (un)substituted alkyl, (un)substituted cycloalkyl, and aryl; each R11 = H, (un)substituted alkyl, (un)substituted cycloalkyl, heterocycloalkyl, Ph, naphthyl, and heteroarom., provided that any of the alkyl, cycloalkyl, Ph, naphthyl, or heteroarom. is optionally substituted with up to 3 substituents = halogen, alkyl, -CF<sub>3</sub>, -OR<sub>12</sub>, -SR<sub>12</sub>, -CN, -NO<sub>2</sub>, -N<sub>3</sub>, -N(R<sub>12</sub>)<sub>2</sub>, -C(O)N(R<sub>12</sub>)<sub>2</sub>, and -C(S)-N(R<sub>12</sub>)<sub>2</sub>; each R<sub>12</sub> = H, alkyl, and cycloalkyl, provided that any of the alkyl or cycloalkyl is optionally substituted with up to 2 substituents = halogen, -CF<sub>3</sub>, -NO<sub>2</sub>, -NH<sub>2</sub>, -N<sub>3</sub>, -CN, -OH, -O-lower alkyl, and -O-lower substituted alkyl.


**IT** 512204-84-1P, (3R)-9-Methyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine 512204-88-5P, (3S)-9-Methyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine 512204-89-6P, (3R)-6-(Phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-

carbazol-3-amine **512204-90-9P**, (3S)-6-(Phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine **512204-92-1P**,  
 (3S)-N,9-Dimethyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine **512204-93-2P**, (3R)-N,9-Dimethyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine **512204-95-4P**  
 RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (candidate drug and positron-emission tomog. uses; preparation of arylsulfonyl-substituted tetrahydro- and hexahydrocarbazolamines as 5-HT<sub>6</sub> receptor ligands)

RN 512204-84-1 HCAPLUS

CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-9-methyl-6-(phenylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 512204-88-5 HCAPLUS

CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-9-methyl-6-(phenylsulfonyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 512204-89-6 HCAPLUS


CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-6-(phenylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 512204-90-9 HCAPLUS  
CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-6-(phenylsulfonyl)-, (3S)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 512204-92-1 HCAPLUS  
CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-N,9-dimethyl-6-(phenylsulfonyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 512204-93-2 HCAPLUS  
CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-N,9-dimethyl-6-(phenylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 512204-95-4 HCAPLUS  
CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-6-(phenylsulfonyl)- (9CI)  
(CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 9 HCPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1998:542759 HCPLUS  
 DOCUMENT NUMBER: 129:175548  
 TITLE: Preparation of benzofurans and benzothiienes as serotonin 5-HT1f agonists  
 INVENTOR(S): Fritz, James E.; Kaldor, Stephen W.; Liang, Sidney Xi; Singh, Upinder; Xu, Yao-chang  
 PATENT ASSIGNEE(S): Eli Lilly and Co., USA  
 SOURCE: U.S., 30 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5792763	A	19980811	US 1997-938739	19970926
PRIORITY APPLN. INFO.:			US 1997-938739	19970926
OTHER SOURCE(S):	MARPAT	129:175548		
GI				



AB The title compds. [I; X = O, S; Y = R4C(O)NH, R5R6NC(Q)NH, R7OC(O)NH, R8SO2NH; Z = N-(un)substituted piperidin-4-yl, (un)substituted 2-aminoethyl; R, R1 = H, C1-4 alkyl, R2 = C1-4 alkyl, C3-8 cycloalkyl, etc.; R3 = H, C1-4 alkyl; R4 = C1-4 alkyl, C3-7 cycloalkyl, (un)substituted Ph, etc.; R5, R6 = H, C1-6 alkyl, C3-6 alkenyl, etc.; R5R6N = pyrrolidine, piperidine, piperazine, etc.; R7 = C1-6 alkyl, C3-6 alkenyl, (un)substituted Ph, etc.; R8 = C1-4 alkyl, (un)substituted Ph, di(C1-4 alkyl)amino; Q = S, O], useful for the prevention and treatment of migraine and associated disorders, were prepared and formulated. Thus, reaction of 5-amino-3-(N',N'-dimethyl-2-aminoethyl)benzothiophene with 4-fluorobenzoyl chloride in the presence of pyridine in CH<sub>2</sub>Cl<sub>2</sub> afforded 44% I oxalate [R = H; Z = CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>; 4-FC<sub>6</sub>H<sub>4</sub>CONH]. Representative compds. I were found to have an affinity at the 5-HT1F receptor of Ki < 1.5 μM.


IT 76243-03-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of benzofurans and benzothiienes as serotonin 5-HT1f agonists)

RN 76243-03-3 HCPLUS

CN 1H-Carbazol-6-ol, 3-(dimethylamino)-2,3,4,4a,9,9a-hexahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 9 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:558789 HCPLUS

DOCUMENT NUMBER: 121:158789

TITLE: Polymerizable dipeptides: preparation, polymerization, and use of polymers for the chromatographic separation of enantiomers

INVENTOR(S): Lange, Walter; Grosse-Bley, Michael; Boemer, Bruno; Grosser, Rolf; Hoever, Franz Peter

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Eur. Pat. Appl., 15 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 584664	A1	19940302	EP 1993-112946	19930812
EP 584664	B1	19981104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 4228135	A1	19940303	DE 1992-4228135	19920825
AT 172986	E	19981115	AT 1993-112946	19930812
ES 2124275	T3	19990201	ES 1993-112946	19930812
JP 06192289	A2	19940712	JP 1993-226539	19930819
CA 2104510	AA	19940226	CA 1993-2104510	19930820
US 6559334	B1	20030506	US 1994-290047	19940812
PRIORITY APPLN. INFO.:			DE 1992-4228135	A 19920825
			US 1993-108369	B1 19930818

OTHER SOURCE(S): MARPAT 121:158789

AB Polymerizable optically active CH<sub>2</sub>:CHR<sub>2</sub>CONHCHR<sub>1</sub>CONHCHR<sub>3</sub>COXR<sub>4</sub> [I, R<sub>1</sub>, R<sub>3</sub> = alkyl, cycloalkyl, aryl, or aralkyl, R<sub>2</sub> = H, Me, or F, X = O or NR<sub>5</sub>, R<sub>4</sub> = alkyl, (substituted) cycloalkyl, (substituted) Ph, or aralkyl, R<sub>5</sub> = H, Me, Et, or forms C<sub>5</sub>-6 cycloalkyl ring with R<sub>4</sub>] are manufactured by preparation of R<sub>1</sub>CH(NHB)CONHCHR<sub>3</sub>CO<sub>2</sub>H (R<sub>1</sub> and R<sub>3</sub> = same as in I, B = removable group) by a standard coupling reaction for peptide formation, removal of B, and reaction of the product with CH<sub>2</sub>:CR<sub>2</sub>COY (R<sub>2</sub> = same as in I, Y = F, Cl, Br, or OCOCR<sub>2</sub>:CH<sub>2</sub>). Alternatively, I are prepared by reaction of CH<sub>2</sub>:CHR<sub>2</sub>CONHCHR<sub>1</sub>CO<sub>2</sub>H (R<sub>1</sub> and R<sub>2</sub> = same as in I) with NH<sub>2</sub>CHR<sub>3</sub>COXR<sub>4</sub> (R<sub>3</sub>, R<sub>4</sub>, and X = same as in I). Thus, reaction of N-acryloyl-S-phenylalanine with

S-phenylalanine iso-Pr ester in the presence of 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline gave N-acryloyl-S-phenylalanine-S-phenylalanine iso-Pr ester (II). Polymerization of II with vinyltrichlorosilane-treated silica

gel gave a product with N content 1.3% and bonded polymer content 11.1%.

IT 116650-17-0


RL: USES (Uses)

(chromatog. separation of, optically active unsatd. dipeptide polymers for)

RN 116650-17-0 HCPLUS

CN 9H-Carbazole-9-propanoic acid, 3-[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4,4a,9a-hexahydro-, (3 $\alpha$ ,4a $\beta$ ,9a $\beta$ )- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L12 ANSWER 4 OF 9 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1991:449398 HCPLUS

DOCUMENT NUMBER: 115:49398

TITLE: Cycloalkano[1,2-b]indolessulfonamides

INVENTOR(S): Boeshagen, Horst; Rosentreter, Ulrich; Lieb, Folker; Oediger, Hermann; Seuter, Friedel; Perzborn, Elisabeth; Fiedler, Volker Bernd

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: U.S., 25 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English




FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4988820	A	19910129	US 1990-556592	19900720
DE 3631824	A1	19880331	DE 1986-3631824	19860919
US 4827032	A	19890502	US 1988-212840	19880629
US 4904797	A	19900227	US 1989-308152	19890208
US 4965258	A	19901023	US 1989-442043	19891128
PRIORITY APPLN. INFO.:		DE 1986-3605562	A	19860221
		DE 1986-3631824	A	19860919
		US 1987-13302	B1	19870210
		US 1988-212840	A3	19880629
		US 1989-308152	A3	19890208
		US 1989-442043	A3	19891128
		DE 1986-3605566	A1	19860221

OTHER SOURCE(S): MARPAT 115:49398

GI



AB Title compds. I [R1 = H, halo, CF<sub>3</sub>, carboxy, alkoxy carbonyl, SOR<sub>3</sub>; R3 = alkyl, aryl, NR<sub>4</sub>R<sub>5</sub>, m = 0, 1, 2; R4, R5 = H, alkyl, aryl, aralkyl, acetyl, OR<sub>6</sub>; R6 = H, alkyl, aryl, aralkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, CF<sub>3</sub>, (substituted) alkyl, (substituted) alkenyl, (substituted) cycloalkyl; R2 = (substituted) aryl, x = 1, 2, 3; y = 0, 1; R7 = R8 = H, R7R8 = bond] were prepared. Thus, (fluorophenylsulfonamidomethyl-1)cyclopentanone II (preparation given) was treated with PhNNHNH<sub>2</sub> to give 3.7% (fluorophenylsulfonamidomethyl)cyclopentanoindole III (R9 = R10 = H), which reacted with CH<sub>2</sub>:CHCN in 40% PhCH<sub>2</sub>Me<sub>3</sub>N+OH--MeOH in dioxane to give 95% III (R9 = R10 = CH<sub>2</sub>CH<sub>2</sub>CN). Hydrolysis of the latter compound gave 87% III (R9 = CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Na, R10 = H), which showed a min. concentration for inhibition

of blood platelet aggregation of 0.03-0.01 mg/kg. I are also useful as thromboxane A<sub>2</sub> antagonists.

IT 116650-18-1P 116650-19-2P 116650-20-5P

134461-03-3P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and blood platelet aggregation inhibiting activity of)

RN 116650-18-1 HCPLUS

CN 9H-Carbazole-9-propanoic acid, 3-[[[4-fluorophenyl)sulfonyl]amino]-1,2,3,4,4a,9a-hexahydro-, (3 $\alpha$ ,4a $\alpha$ ,9a $\alpha$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 116650-19-2 HCPLUS

CN 9H-Carbazole-9-propanoic acid, 1,2,3,4,4a,9a-hexahydro-3-[(phenylsulfonyl)amino]-, (3 $\alpha$ ,4a $\beta$ ,9a $\beta$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 116650-20-5 HCPLUS


CN 9H-Carbazole-9-propanoic acid, 1,2,3,4,4a,9a-hexahydro-3-[(phenylsulfonyl)amino]-, (3 $\alpha$ ,4a $\alpha$ ,9a $\alpha$ )- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 134461-03-3 HCPLUS

CN 9H-Carbazole-9-propanoic acid, 3-[[4-chlorophenyl]sulfonyl]amino]-6-fluoro-1,2,3,4,4a,9a-hexahydro- (9CI) (CA INDEX NAME)




IT 116650-17-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as intermediate in synthesis of platelet aggregation inhibitors)

RN 116650-17-0 HCPLUS

CN 9H-Carbazole-9-propanoic acid, 3-[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4,4a,9a-hexahydro-, (3 $\alpha$ ,4a $\beta$ ,9a $\beta$ )- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 116650-21-6P 116650-22-7P 134461-01-1P


134461-02-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as intermediate in synthesis of platelet aggregation inhibitors or thromboxane A<sub>2</sub> antagonist)

RN 116650-21-6 HCPLUS

CN 9H-Carbazole-9-propanoic acid, 1,2,3,4,4a,9a-hexahydro-3-[(4-methylphenyl)sulfonyl]amino]-, (3 $\alpha$ ,4a $\beta$ ,9a $\beta$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 116650-22-7 HCAPLUS


CN 9H-Carbazole-9-propanoic acid, 1,2,3,4,4a,9a-hexahydro-3-[(4-methylphenyl)sulfonyl]amino]-, (3 $\alpha$ ,4 $\alpha$ ,9 $\alpha$ )- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 134461-01-1 HCAPLUS

CN Benzenesulfonamide, 4-chloro-N-(6-fluoro-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-yl)- (9CI) (CA INDEX NAME)



RN 134461-02-2 HCAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2-cyanoethyl)-N-[9-(2-cyanoethyl)-6-fluoro-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-yl]- (9CI) (CA INDEX NAME)



L12 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1991:186288 HCAPLUS

DOCUMENT NUMBER: 114:186288

TITLE: Optically active (meth)acrylamide derivative preparation, polymerization, and use in chromatographic resolution

INVENTOR(S): Lange, Walter; Boemer, Bruno; Grosser, Rolf; Arlt, Dieter

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Eur. Pat. Appl., 27 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 379917	A2	19900801	EP 1990-100703	19900113
EP 379917	A3	19920226		
EP 379917	B1	19950809		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL ES 2077591				
ES 2077591	T3	19951201	ES 1990-100703	19900113
JP 02264752	A2	19901029	JP 1990-11972	19900123
JP 2812765	B2	19981022		
US 5274167	A	19931228	US 1992-835169 DE 1989-3902287 JP 1989-11972 US 1990-467111	19920213 A 19890126 A 19890126 A2 19900118
PRIORITY APPLN. INFO.:				

OTHER SOURCE(S): MARPAT 114:186288

AB The optically active amides H<sub>2</sub>C:C(R)CON(R<sub>3</sub>)C(R<sub>1</sub>)HCOXR<sub>2</sub> [R = H, Me; R<sub>1</sub> = alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl; R<sub>3</sub> = H, R<sub>1</sub>, trimethylene, tetramethylene; R<sub>2</sub> = bulky hydrocarbyl, tertiary alkyl, cycloalkyl, aryl, heteroaryl, terpenyl, adamantyl; X = O, imino] are prepared, polymerized, and used as column packings in chromatog. determination and resolution of racemic mixts.

Thus, D-alanine 1-menthyl ester hydrochloride was condensed with acryloyl chloride to give an amide ([α]<sub>D</sub> -67.0°), 13.5 g of which was polymerized with 1.50 g ethylene dimethacrylate in the presence of AIBN to give a copolymer which was used in the resolution of 3-(4-chlorophenylsulfonamido)-9-(2-carboxylethyl)-1,2,3,4-tetrahydrocarbazole.


IT 133287-23-7

RL: PROC (Process)


(resolution of, optically active acrylamide polymers for)

RN 133287-23-7 HCPLUS

CN 9H-Carbazole-9-propanoic acid, 1,2,3,4,4a,9a-hexahydro-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)





ACCESSION NUMBER: 1991:6215 HCPLUS  
 DOCUMENT NUMBER: 114:6215  
 TITLE: Synthesis of tritium-labeled (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-[4-3H] carbazolepropanoic acid  
 AUTHOR(S): Pleiss, Ulrich; Radtke, Martin; Schmitt, Peter  
 CORPORATE SOURCE: Inst. Pharmacokinet., Bayer A.-G., Wuppertal, D-5600, Germany  
 SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals (1990), 28(9), 1081-6  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 114:6215  
 AB The preparation of the title compound ([3H]Bay u 3405) (I) starting from Bay u 3405 via oxidation and catalytic tritiation is described. In the tritium NMR spectrum of I the ratio of 4 $\alpha$ -3H and 4 $\beta$ -3H was 1:1.  
 IT 130966-74-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and oxidation of)  
 RN 130966-74-4 HCPLUS  
 CN 9H-Carbazole-9-propanoic acid, 3-[(4-fluorophenyl)sulfonyl]amino-1,2,3,4,4a,9a-hexahydro-, methyl ester, (R)- (9CI) (CA INDEX NAME)



L12 ANSWER 7 OF 9 HCPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1989:75309 HCPLUS  
 DOCUMENT NUMBER: 110:75309  
 TITLE: Preparation of cycloalkano[1,2-b]indole-substituted arenesulfonamides as blood platelet aggregation inhibitors  
 INVENTOR(S): Boshagen, Horst; Rosentreter, Ulrich; Lieb, Folker; Oediger, Hermann; Seuter, Friedel; Perzborn, Elisabeth; Fredler, Volker Bernd  
 PATENT ASSIGNEE(S): Bayer A.-G., Fed. Rep. Ger.  
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 82 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Chinese  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 87100773	A	19870902	CN 1987-100773	19870221

CN 1015711	B 19920304			
DE 3631824	A1 19880331	DE 1986-3631824	19860919	
PRIORITY APPLN. INFO.:		DE 1986-3605566	A 19860221	
		DE 1986-3631824	A 19860919	
OTHER SOURCE(S):	CASREACT 110:75309			
GI				



AB The title compds. [I; R1 = H, halo, CF<sub>3</sub>, CO<sub>2</sub>H, alkoxy carbonyl, R<sub>3</sub>S(O)m wherein R<sub>3</sub> = (substituted) amino, m = 0, 1, 2; R<sub>2</sub> = (substituted) aryl; x = 1, 2, 3; y = 0, 1; 2,3-saturated or unsatd.] and their stereoisomers or salts are prepared Cyanoethylation of cyclopentindole derivative II (R<sub>3</sub> = R<sub>4</sub> = H) with acrylonitrile in the presence of PhCH<sub>2</sub>N+Me<sub>3</sub> OH- in MeOH gave 95% propionitrile derivative II (R<sub>3</sub> = R<sub>4</sub> = CH<sub>2</sub>CH<sub>2</sub>CN), which was hydrolyzed with 10% NaOH in MeOH to give 96.2% II (R<sub>3</sub> = CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, R<sub>4</sub> = H) as the Na salt. I showed effective control of platelet aggregation at 0.01-10 mg/kg in vitro. I may be administered in various routes and the preferred dose is 0.01-0.5 mg/kg i.v. and 0.1-10 mg/kg p.o. Various synthetic schemes are also given.

IT 116650-17-0P 116650-18-1P 116650-19-2P


116650-21-6P 116650-22-7P 118699-42-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as blood platelet aggregation inhibitor)

RN 116650-17-0 HCAPLUS

CN 9H-Carbazole-9-propanoic acid, 3-[[[4-fluorophenyl)sulfonyl]amino]-1,2,3,4,4a,9a-hexahydro-, (3 $\alpha$ ,4a $\beta$ ,9a $\beta$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 116650-18-1 HCPLUS

CN 9H-Carbazole-9-propanoic acid, 3-[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4,4a,9a-hexahydro-, (3 $\alpha$ ,4 $\alpha\alpha$ ,9 $\alpha\alpha$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 116650-19-2 HCPLUS

CN 9H-Carbazole-9-propanoic acid, 1,2,3,4,4a,9a-hexahydro-3-[(phenylsulfonyl)amino]-, (3 $\alpha$ ,4 $\alpha\beta$ ,9 $\alpha\beta$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 116650-21-6 HCPLUS

CN 9H-Carbazole-9-propanoic acid, 1,2,3,4,4a,9a-hexahydro-3-[(4-methylphenyl)sulfonyl]amino]-, (3 $\alpha$ ,4 $\alpha\beta$ ,9 $\alpha\beta$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 116650-22-7 HCAPLUS

CN 9H-Carbazole-9-propanoic acid, 1,2,3,4,4a,9a-hexahydro-3-[(4-methylphenyl)sulfonyl]amino]-, (3a,4aalpha,9aalpha)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 118699-42-6 HCAPLUS

CN 9H-Carbazole-9-propanoic acid, 1,2,3,4,4a,9a-hexahydro-alpha,b-dioxo-3-[(phenylsulfonyl)amino]-, (3a,4aalpha,9aalpha)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L12 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1988:630800 HCAPLUS

DOCUMENT NUMBER: 109:230800



TITLE: Cycloalkano[1,2-b]indolesulfonamides, procedure for their preparation, drugs containing them, and their

use  
INVENTOR(S) : Boeshagen, Horst; Rosentreter, Ulrich; Lieb, Folker;  
Oediger, Hermann; Seuter, Friedel; Perzborn,  
Elisabeth; Fiedler, Volker Bernd  
PATENT ASSIGNEE(S) : Bayer A.-G., Fed. Rep. Ger.  
SOURCE: Ger. Offen., 48 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3631824	A1	19880331	DE 1986-3631824	19860919
NO 8700437	A	19870824	NO 1987-437	19870204
NO 171633	B	19930104		
NO 171633	C	19930414		
EP 242518	A1	19871028	EP 1987-101901	19870211
EP 242518	B1	19910410		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 62477	E	19910415	AT 1987-101901	19870211
ES 2028801	T3	19920716	ES 1987-101901	19870211
AU 8768808	A1	19870827	AU 1987-68808	19870213
AU 595855	B2	19900412		
IL 81611	A1	19910310	IL 1987-81611	19870218
FI 8700693	A	19870822	FI 1987-693	19870219
FI 86544	B	19920529		
FI 86544	C	19920910		
HU 44493	A2	19880328	HU 1987-650	19870219
HU 198686	B	19891128		
DD 264427	A5	19890201	DD 1987-300047	19870219
CS 275837	B6	19920318	CS 1987-1093	19870219
CS 276468	B6	19920617	CS 1988-6891	19870219
CS 276469	B6	19920617	CS 1988-6892	19870219
CA 1309414	A1	19921027	CA 1987-530077	19870219
DK 8700871	A	19870822	DK 1987-871	19870220
DK 167009	B1	19930816		
ZA 8701249	A	19871028	ZA 1987-1249	19870220
SU 1438609	A3	19881115	SU 1987-4202045	19870220
CN 87100773	A	19870902	CN 1987-100773	19870221
CN 1015711	B	19920304		
JP 62198659	A2	19870902	JP 1987-36920	19870221
JP 04050301	B4	19920813		
US 4827032	A	19890502	US 1988-212840	19880629
US 4904797	A	19900227	US 1989-308152	19890208
US 4965258	A	19901023	US 1989-442043	19891128
AU 9054817	A1	19900913	AU 1990-54817	19900508
AU 633563	B2	19930204		
US 4988820	A	19910129	US 1990-556592	19900720
JP 05092954	A2	19930416	JP 1992-76232	19920227
JP 07005552	B4	19950125		
PRIORITY APPLN. INFO. :			DE 1986-3605566	A1 19860221
			DE 1986-3605562	A 19860221
			DE 1986-3631824	A 19860919
			US 1987-13302	A1 19870210
			EP 1987-101901	A 19870211
			US 1988-212840	A3 19880629
			US 1989-308152	A3 19890208

OTHER SOURCE(S) :  
GI

MARPAT 109:230800



AB The title compds. I [R1 = H, halo, CF3, CO2H, (un)substituted NH2, etc.; R2 (un)substituted aryl; x = 1-3; y = 0, 1] optionally in an isomeric form, and their salts, useful as thrombocyte aggregation inhibitors and thromboxane A2 antagonists and of significance in veterinary medicine, were prepared. Cyclopentanoindole II (R = CH2CH2CO2Na) (III) was prepared in 2 steps from II (R = H), which was prepared from 3-(4-fluorobenzenesulfonamidomethyl)cyclopentanone (IV) and PhNNH2. IV was prepared in 3 steps from 2-cyclopentenone and MeNO2 in the presence of 1,5-diazabicyclo[4.3.0]non-5-ene. The min. inhibitory concentration of III for thrombocyte aggregation inhibition was 0.03-0.01 mg/kg.


IT 116650-17-0P 116650-18-1P 116650-19-2P  
116650-20-5P 116650-21-6P 116650-22-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as thrombocyte aggregation inhibitor)

RN 116650-17-0 HCPLUS

CN 9H-Carbazole-9-propanoic acid, 3-[[ (4-fluorophenyl)sulfonyl]amino]-1,2,3,4,4a,9a-hexahydro-, (3 $\alpha$ ,4a $\beta$ ,9a $\beta$ )- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10/12/2005 10777252.trn

RN 116650-18-1 HCAPLUS

CN 9H-Carbazole-9-propanoic acid, 3-[[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4,4a,9a-hexahydro-, (3 $\alpha$ ,4a $\alpha$ ,9a $\alpha$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 116650-19-2 HCAPLUS

CN 9H-Carbazole-9-propanoic acid, 1,2,3,4,4a,9a-hexahydro-3-[(phenylsulfonyl)amino]-, (3 $\alpha$ ,4a $\beta$ ,9a $\beta$ )- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 116650-20-5 HCAPLUS

CN 9H-Carbazole-9-propanoic acid, 1,2,3,4,4a,9a-hexahydro-3-[(phenylsulfonyl)amino]-, (3 $\alpha$ ,4a $\alpha$ ,9a $\alpha$ )- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 116650-21-6 HCAPLUS

CN 9H-Carbazole-9-propanoic acid, 1,2,3,4,4a,9a-hexahydro-3-[[[(4-methylphenyl)sulfonyl]amino]-, (3 $\alpha$ ,4a $\beta$ ,9a $\beta$ )- (9CI) (CA INDEX NAME)

INDEX NAME)


Relative stereochemistry.



RN 116650-22-7 HCPLUS

CN 9H-Carbazole-9-propanoic acid, 1,2,3,4,4a,9a-hexahydro-3-[(4-methylphenyl)sulfonyl]amino]-, (3a,4a,9a)- (9CI) (CA  
INDEX NAME)

Relative stereochemistry.



L12 ANSWER 9 OF 9 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1981:47136 HCPLUS

DOCUMENT NUMBER: 94:47136

TITLE: Tetrahydrocarbazoles and pharmaceutical compositions  
for treating heart failure in mammals

INVENTOR(S): Mooradian, Aram

PATENT ASSIGNEE(S): Sterling Drug Inc., USA

SOURCE: U.S., 7 pp. Cont.-in-part of U.S. Ser. No. 465,238,  
abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4224335	A	19800923	US 1976-651882	19760123
US 3642816	A	19720215	US 1967-659606	19670810
US 3959309	A	19760525	US 1973-425205	19731217
PRIORITY APPLN. INFO.:			US 1967-659606	A2 19670810

US 1969-793545	A2 19690123
US 1971-172206	A2 19710816
US 1973-425205	A2 19731217
US 1974-465238	A2 19740429
CA 1968-10686	A 19680124

GI




**AB** The carbazoles I (R = H, Me; R1 = NH<sub>2</sub>, EtNH, Me<sub>2</sub>N; R2 = 5-, 6-, 7-HO; R3 = H, 7-F, 7-HO) were prepared. Thus, m-PhCH<sub>2</sub>OOC<sub>6</sub>H<sub>4</sub>NMe<sub>2</sub>HCl was cyclized with 4-(dimethylamino)cyclohexanone to give I (R = Me, R1 = Me<sub>2</sub>N, R2 = 7-PhCH<sub>2</sub>O, R3 = H), which was debenzylated to give I (R = Me, R1 = Me<sub>2</sub>N, R2 = 7-HO, R3 = H). I underwent cardiotonic tests and were found useful for treatment of congestive heart failure in mammals.

**IT** 76243-30-6 76243-31-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(debenzylation of)


RN 76243-30-6 HCPLUS

CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-N,N-dimethyl-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 76243-31-7 HCPLUS

CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-N,N-dimethyl-6-(phenylmethoxy)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

**IT** 76243-19-1P 76243-27-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and debenzylation of)

RN 76243-19-1 HCPLUS

CN Acetamide, N-[2,3,4,4a,9,9a-hexahydro-7-(phenylmethoxy)-1H-carbazol-3-yl]-


10/12/2005 10777252.trn

(9CI) (CA INDEX NAME)



RN 76243-27-1 HCPLUS

CN 1H-Carbazol-3-amine, 7-fluoro-2,3,4,4a,9,9a-hexahydro-N,N-dimethyl-6-(phenylmethoxy)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

IT 76243-05-5P 76243-06-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and hydrogenolysis of)

RN 76243-05-5 HCPLUS


CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-N,N,9-trimethyl-7-(phenylmethoxy)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 76243-06-6 HCPLUS

CN 1H-Carbazol-3-amine, 2,3,4,4a,9,9a-hexahydro-N,N,9-trimethyl-5-(phenylmethoxy)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


IT 76243-20-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and hydrolysis of)  
 RN 76243-20-4 HCAPLUS  
 CN Acetamide, N-(2,3,4,4a,9,9a-hexahydro-7-hydroxy-1H-carbazol-3-yl)- (9CI)  
 (CA INDEX NAME)



IT 76243-10-2P 76243-14-6P 76243-32-8P  
 76254-53-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 76243-10-2 HCAPLUS  
 CN 1H-Carbazol-7-ol, 3-(dimethylamino)-2,3,4,4a,9,9a-hexahydro-9-methyl-,  
 methanesulfonate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 76243-09-9  
 CMF C15 H22 N2 O




CM 2

CRN 75-75-2  
 CMF C H4 O3 S



RN 76243-14-6 HCAPLUS  
CN 1H-Carbazole-6,7-diol, 3-(dimethylamino)-2,3,4,4a,9,9a-hexahydro-, hydrobromide (9CI) (CA INDEX NAME)




●x HBr

RN 76243-32-8 HCAPLUS  
CN 1H-Carbazol-6-ol, 3-(dimethylamino)-2,3,4,4a,9,9a-hexahydro-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 76243-03-3  
CMF C<sub>14</sub> H<sub>20</sub> N<sub>2</sub> O




CM 2

CRN 75-75-2  
CMF C H<sub>4</sub> O<sub>3</sub> S




RN 76254-53-0 HCAPLUS  
CN 1H-Carbazole-6,7-diol, 3-(ethylamino)-2,3,4,4a,9,9a-hexahydro-, hydrobromide (9CI) (CA INDEX NAME)




●x HBr

IT 76243-03-3P 76243-04-4P 76243-07-7P  
 76243-08-8P 76243-13-5P 76243-17-9P  
 76243-18-0P 76243-21-5P 76243-29-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, for treatment of congestive heart failure)  
 RN 76243-03-3 HCPLUS  
 CN 1H-Carbazol-6-ol, 3-(dimethylamino)-2,3,4,4a,9,9a-hexahydro- (9CI) (CA INDEX NAME)




RN 76243-04-4 HCPLUS  
 CN 1H-Carbazol-6-ol, 3-(dimethylamino)-2,3,4,4a,9,9a-hexahydro-,  
 hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 76243-07-7 HCPLUS  
 CN 1H-Carbazol-5-ol, 3-(dimethylamino)-2,3,4,4a,9,9a-hexahydro-9-methyl-,  
 hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 76243-08-8 HCPLUS  
CN 1H-Carbazol-7-ol, 3-(dimethylamino)-2,3,4,4a,9,9a-hexahydro-9-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 76243-13-5 HCPLUS  
CN 1H-Carbazole-6,7-diol, 3-(dimethylamino)-2,3,4,4a,9,9a-hexahydro-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 76243-17-9 HCPLUS  
CN 1H-Carbazole-6,7-diol, 3-(ethylamino)-2,3,4,4a,9,9a-hexahydro-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 76243-18-0 HCPLUS  
CN 1H-Carbazole-6,7-diol, 3-amino-2,3,4,4a,9,9a-hexahydro-, hydrochloride  
(9CI) (CA INDEX NAME)



●x HCl

RN 76243-21-5 HCPLUS  
CN 1H-Carbazol-7-ol, 3-amino-2,3,4,4a,9,9a-hexahydro-, hydrochloride (9CI)  
(CA INDEX NAME)




●x HCl

RN 76243-29-3 HCPLUS  
CN 1H-Carbazol-6-ol, 3-(dimethylamino)-7-fluoro-2,3,4,4a,9,9a-hexahydro-,  
monomethanesulfonate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 76243-28-2  
CMF C14 H19 F N2 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S



=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	59.24	551.75
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-8.03	-8.76

STN INTERNATIONAL LOGOFF AT 09:37:35 ON 12 OCT 2005